NTLA: Late-stage gene editing therapies for HAE and TTR advance, with FDA review and strong market prospects
The company is advancing in vivo gene editing with late-stage programs for HAE and TTR, expecting FDA approval for its HAE therapy by March 10. Strong efficacy and safety data support broad market potential, with a targeted commercial launch and robust financial runway enabling future pipeline inve…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.